Background/Aim: Advanced melanoma treatment remains debated, particularly in patients with B-Raf proto-oncogene serine/threonine kinase (BRAF) V600 mutations eligible for both immune checkpoint inhibitors (ICI) and BRAF/MEK inhibitors. Additional biomarkers are needed to improve treatment selection. Mutations of the te...
P. Marchese, Irene Zannini, D. de Biase et al.· Anticancer Research· 0 citations
Background/Objectives: Cutaneous adverse events (cAEs) are among the most common toxicities associated with modern anticancer therapies and can significantly affect quality of life, treatment adherence, and therapeutic outcomes. This narrative review aims to provide an updated overview of the mechanisms, clinical manif...
Simple Summary Nevus-associated melanoma, a melanoma arising in association with a pre-existing melanocytic nevus, accounts for approximately one-quarter of all cutaneous melanomas and is usually diagnosed at an early stage. Although thin nevus-associated melanomas generally have an excellent prognosis, a small proport...
Federico Venturi, Maria Luisa Orlando, Barbara Corti et al.· Cancers· 0 citations
Cutaneous melanoma is a malignant tumor and remains a clinical challenge due to unmet needs in risk stratification, real-time treatment monitoring, and early detection of progression or resistance. Early detection is crucial, as prognosis significantly worsens once metastasis occurs. Liquid biopsy has emerged as a powe...
E. Broseghini, G. Durante, A. Soru et al.· Frontiers in Cell and Develo...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
